Valuation: Tonix Pharmaceuticals

Market Cap 157M 138M 129M 118M 222M 15.17B 225M 1.53B 597M 7.46B 591M 578M 25.78B P/E 2026 *
-0.98x
P/E 2027 * -1.57x
Enterprise Value 157M 138M 129M 118M 222M 15.17B 225M 1.53B 597M 7.46B 591M 578M 25.78B EV / Sales 2026 *
4.61x
EV / Sales 2027 * 2x
Free-Float
99.86%
Yield 2026 *
-
Yield 2027 * -
07-15 Tonix Pharmaceuticals Advances Tnx-801 Live Attenuated Minimally Replicative Investigational Vaccine Candidate Based on Horsepox Virus to Protect Against Mpox Disease CI
07-13 Tonix Pharmaceuticals Holding Corp. Announces Major Managed Medicare Agreement for Tonmya and Expands Pharmacy Coverage CI
07-13 Tonix Pharmaceuticals Reaches Medicare Coverage Deal for Fibromyalgia Treatment MT
06-29 Tonix Pharmaceuticals Advances TNX-102 SL Into Phase 2 MDD Study MT
06-29 Tonix Pharmaceuticals Holding Corp Announces First Patient Enrolled in Phase 2 Horizon Study of TNX-102 SL For Major Depressive Disorder CI
06-25 Raymond James Initiates Coverage on Tonix Pharmaceuticals With Strong Buy Rating, $26 PT MT
06-08 Tonix Pharmaceuticals Enters Second Commercial Payer Deal, Expands Drug Coverage MT
06-08 Tonix Pharmaceuticals Holding Corp. Enters Agreement With Group Purchasing Organization For Commercial Coverage Of TONMYA CI
05-29 Tonix Pharmaceuticals Holding Corp. Presents Data from Real-World Claims Analysis of Opioid Use in U.S. Adults with Fibromyalgia at 2026 ASCP Annual Meeting CI
05-27 Tonix Pharmaceuticals Holding Corp. Announces Publication Of Phase 1 Clinical Data Of TNX-1500 Fc-Modified Anti-CD40L Monoclonal Antibody CI
05-26 Tonix Pharmaceuticals Presents Real-World Claims Analysis And Launches TONMYA For Fibromyalgia Treatment CI
05-12 Tranche Update on Tonix Pharmaceuticals Holding Corp.'s Equity Buyback Plan announced on September 6, 2024. CI
05-12 Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
Manager TitleAgeSince
Chief Executive Officer 68 16/11/2007
Director of Finance/CFO 52 01/02/2016
Chief Tech/Sci/R&D Officer 57 04/02/2025
Director TitleAgeSince
Chairman 68 01/10/2011
Director/Board Member 66 12/09/2017
Director/Board Member 81 05/09/2018
Change 5-day change 1-year change 3-year change Capi.($)
-2.36%+2.32% - - 157M
+0.86%+1.43%+48.50%+160.39% 1,067B
+1.59%+4.09%+55.34%+53.96% 635B
+0.95%+1.91%+35.91%+81.14% 458B
+1.60%+6.25%+33.95%+29.84% 347B
-0.60%+1.52%+35.68%+39.76% 295B
-0.14%+0.60%+16.17%+17.53% 262B
+0.09%-2.82%-28.29%-41.71% 216B
+1.22%+2.66%+21.87%+59.73% 203B
-1.18%-3.70%+14.23%+66.51% 161B
Average +0.10%+1.33%+25.93%+51.91% 404.78B
Weighted average by Cap. +0.55%+1.95%+35.81%+77.68%

Financials

2026 *2027 *
Net sales 34.18M 30.02M 27.92M 25.62M 48.14M 3.29B 48.88M 332M 130M 1.62B 128M 126M 5.6B 78.93M 69.33M 64.47M 59.16M 111M 7.6B 113M 766M 299M 3.74B 296M 290M 12.92B
Net income -170M -149M -139M -127M -239M -16.37B -243M -1.65B -644M -8.05B -638M -624M -27.82B -152M -133M -124M -114M -214M -14.62B -217M -1.47B -575M -7.19B -570M -558M -24.85B
Net Debt - -
Logo Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
9.880USD
Average target price
42.20USD
Spread / Average Target
+327.13%

Quarterly revenue - Rate of surprise